U.S. FDA Unveils AI Tool Elsa for Clinical Review, Internal Writing, and Data Processing

Jun.04

The U.S. Food and Drug Administration has officially launched Elsa, a generative AI tool designed to speed up clinical reviews, internal writing, and data processing tasks. After successful pilots across multiple departments, Elsa is now being rolled out agency-wide.

On June 2, 2025, the United States Food and Drug Administration (FDA) announced on its official website the launch of a new generative artificial intelligence (AI) tool named Elsa. The tool is designed to assist various professionals, including scientific reviewers and researchers, in working more efficiently. This innovative tool aims to modernize agency functions and utilize AI capabilities to better serve the American public.

FDA Director Marty Makary said:

"After collaborating with FDA scientific reviewers on a highly successful pilot project, I developed a proactive timeline to implement artificial intelligence agency-wide by June 30. Thanks to the collaboration of internal experts from our various centers, today's launch of Elsa was completed ahead of schedule and within budget."

Elsa is built in a highly secure GovCloud environment, providing FDA employees with a secure platform to access internal files while ensuring all information remains within the agency. These models will not use data submitted by regulated industries for training, thereby protecting the sensitive research and data handled by FDA employees.

FDA Chief Artificial Intelligence Officer Jeremy Walsh stated:

"The release of Elsa marks the arrival of the FDA's artificial intelligence era. Artificial intelligence is no longer a distant promise, but a powerful force that can enhance and optimize the performance and potential of every employee. As we learn how employees are utilizing this tool, our development team will be able to continuously expand its capabilities and grow based on the needs of employees and organizations."

The organization has been using Elsa to expedite the review of clinical trial protocols, shorten the time needed for scientific evaluation, and identify high-priority research targets.Elsa is an AI tool based on a large language model, designed to assist in reading, writing, and summarizing. It can summarize adverse events to support safety assessments, compare tags more quickly, and generate code to help develop non-clinical applications for databases.

The FDA stated that the launch of Elsa is the first step in its overall AI journey. As this tool matures, the FDA plans to integrate more AI technologies into various processes, such as data processing and generative AI functions, to further support the FDA's mission.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Smoking Among Korean Men in Their 30s Plummets as E-Cigarettes Become the Main Substitute

KDCA reports cigarette smoking among Korean men in their 30s fell from 48% (2015) to 28.5% (2024). Including e-cigarettes, overall use was 40.1% in 2024—just 4.9 points below 2019—suggesting a shift to alternatives.

Oct.09 by 2FIRSTS.ai

South Korea National Assembly Approves Bill to Regulate E-Cigarettes Under Tobacco Law After Nine Years of Debate

South Korea’s National Assembly Legislation and Judiciary Committee passed a long-debated amendment to the Tobacco Business Act on November 26, expanding the legal definition of tobacco to include synthetic nicotine e-cigarettes. The amendment aims to end the regulatory blind spot surrounding such products while ensuring transitional support for vape retailers and a grace period for compliance.

Nov.26 by 2FIRSTS.ai

China Opens 2026 National E-Cigarette Standards Project for Public Submissions

The State Administration for Market Regulation (SAMR) and the State Tobacco Monopoly Administration (STMA) jointly announced the launch of the 2026 National Standardization Project for E-cigarettes. The initiative, coordinated by the National Technical Committee on Standardization of E-cigarettes, aims to enhance the industry’s regulatory framework through new standards on manufacturing, storage, distribution, and evaluation.

Nov.27 by 2FIRSTS.ai

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement

President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.